1-(1-adamantyl)ethane-1,2-diol | 197910-35-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(1-adamantyl)ethane-1,2-diol
• 英文别名: 1-Adamantan-1-yl-ethane-1,2-diol
• CAS: 197910-35-3
• 化学式: C₁₂H₂₀O₂
• 分子量: 196.29
• InChiKey: WATQCEHAJJMVIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(1-adamantyl)ethane-1,2-diol 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 反应 42.0h， 生成
  参考文献：
  名称：

  Preparation of homochiral crown ether containing (S)-1-(1-adamantyl)ethane-1,2-diol as a chiral subunit and its enantioselective complexation with an organic ammonium cation

  摘要：

  Homochiral 1-(1-adamantyl)ethane-1,2-diol(5) was prepared and its absolute configuration was determined to be (S)-(+)-5 by enzymatic and H-1 n.m.r. spectroscopic methods. Using (S)-(+)-5 as a chiral subunit, the homochiral crown ether (+)-18 was synthesized and its enantioselectivity in complexation of methionine methyl ester perchlorate was also examined by the H-1 n.m.r. spectroscopic method.

  DOI：

  10.1016/0957-4166(94)80125-8
• 作为产物：
  描述：

  1-金刚烷乙酰氯 在 吡啶 、 四氧化锇 、 lithium aluminium tetrahydride 、 水 、 双氧水 、 N-甲基吗啉氧化物 作用下， 以 甲醇 、 乙醚 、 叔丁醇 、 苯 为溶剂， 反应 86.0h， 生成 1-(1-adamantyl)ethane-1,2-diol
  参考文献：
  名称：

  Preparation of homochiral crown ether containing (S)-1-(1-adamantyl)ethane-1,2-diol as a chiral subunit and its enantioselective complexation with an organic ammonium cation

  摘要：

  Homochiral 1-(1-adamantyl)ethane-1,2-diol(5) was prepared and its absolute configuration was determined to be (S)-(+)-5 by enzymatic and H-1 n.m.r. spectroscopic methods. Using (S)-(+)-5 as a chiral subunit, the homochiral crown ether (+)-18 was synthesized and its enantioselectivity in complexation of methionine methyl ester perchlorate was also examined by the H-1 n.m.r. spectroscopic method.

  DOI：

  10.1016/0957-4166(94)80125-8

文献信息

• [EN] DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS<br/>[FR] ADMINISTRATION DE COMPOSÉS ALCALOÏDES THÉRAPEUTIQUES
  申请人：SENSORIUM THERAPEUTICS INC

  公开号：WO2023076586A1

  公开（公告）日：2023-05-04

  Disclosed are prodrug compounds that can be converted to mesembrine under biologically relevant conditions, such as hydrolysis in vivo; and related methods of preparing and using these compounds. Stable preparations of isolated mesembrine stereoisomers are also provided.

  所公开的是可在生物相关条件下（如体内水解）转化为美森布林的原药化合物，以及制备和使用这些化合物的相关方法。此外，还提供了分离出的间苯三酚立体异构体的稳定制备方法。
• CENTRIFUGATION DETECTION METHOD AND DEVICE
  申请人：Beijing Kanghuayuan Sci-Tech Company Ltd

  公开号：EP3431990A1

  公开（公告）日：2019-01-23

  A centrifugation detection method and device. The method comprises the following steps: use a centrifuge means (3) to drive a liquid to flow through a solid membrane (2), the liquid comprising a sample to be detected having a substance to be detected and a detection phase; when flowing through the solid membrane (2), the liquid is bound to a substance to be detected-specific binder that envelopes the solid membrane (2), to form a complex consisting of a detection indicator, the substance to be detected, and the substance to be detected-specific binder, the complex is captured and fixed to the solid membrane (2), and a detector (4) detects the amount of the detection indicator indirectly fixed to the solid membrane to detect the content of the substance to be detected. The device comprises a sampling component (1), the solid membrane (2), the centrifuge means (3), and the detector (4). The sampling component (1) is disposed in the middle of a centrifuge rotor (9) and is connected with the centrifuge rotor (9); the solid membrane (2) is disposed on the centrifuge rotor (9) and is connected with a sampling pipe (8); the detector (4) is disposed at one or both sides of the solid membrane (2). The present invention features high sensitivity and short detection time.

  一种离心检测方法和装置。该方法包括以下步骤：使用离心装置 (3) 驱动液体流经固体膜 (2)，液体包括具有待检测物质和检测相的待检测样品；在流经固体膜（2）时，液体与包裹固体膜（2）的待检测物质专用粘合剂结合，形成由检测指示剂、待检测物质和待检测物质专用粘合剂组成的复合物，复合物被捕获并固定在固体膜（2）上，检测器（4）检测间接固定在固体膜上的检测指示剂的量，以检测待检测物质的含量。该装置包括取样组件 (1)、固体膜 (2)、离心装置 (3) 和检测器 (4)。采样部件（1）设置在离心转子（9）的中部，并与离心转子（9）连接；固体膜（2）设置在离心转子（9）上，并与采样管（8）连接；检测器（4）设置在固体膜（2）的一侧或两侧。本发明具有灵敏度高、检测时间短的特点。
• Hirose, Keiji; Fuji, Junichi; Kamada, Kimiko, Journal of the Chemical Society. Perkin Transactions 2 (2001), 1997, # 9, p. 1649 - 1657
  作者：Hirose, Keiji、Fuji, Junichi、Kamada, Kimiko、Tobe, Yoshito、Naemura, Koichiro

  DOI：——

  日期：——
• A METHOD AND KIT FOR DETERMINATION OF THYMIDINE KINASE ACTIVITY AND USE THEREOF
  申请人：Rönnerbol International AB

  公开号：EP1856275B1

  公开（公告）日：2009-08-12
• Method and Kit for Determination of Thymidine Kinase Activity and Use Thereof
  申请人：Gronowitz J. Simon

  公开号：US20080248472A1

  公开（公告）日：2008-10-09

  A method and assay kit for determination of thymidine kinase (TK) activity in a biological sample, such as blood, serum, plasma, Cerebral Spinal Fluid (CSF), pleural fluid, ascites, tissues, cells and extracts thereof, is described. The method comprises contacting, in a buffer, a Basic Reaction Mixture comprising: solid surface-attached primer and/or template, a modified deoxy nucleoside, such as BromodeoxyUridine, IododeoxyUridine, Fluorodeoxy-Uridine or VinyldexoyThymidine as a kinase enzyme substrate, a phosphate donor, a nucleotide polymerizing enzyme, and a kinase enzyme source devoid of TK activity, such as a yeast extract, with the biological sample. After incubation the amount of modified deoxy nucleoside that has been incorporated into the solid surface-attached primer and/or template, is determined and the TK activity present in the biological sample is directly proportional to the amount of incorporated modified deoxy nucleoside. The method and assay kit are useful in the diagnosing, prognosis monitoring of disease progression and treatment effects of cell-proliferation disorders or diseases, such as cancer, and in the screening of compounds, e.g. new drug candidates, affecting enzymatic pathways, which may obstruct the formation of thymidine phosphates or interfere with nucleic acid synthesis.